Ketamine Extension vs. Buprenorphine Maintenance: Clinical Outcomes Compared

Direct Comparison of Ketamine and Buprenorphine in Substance Use Disorder

A peer-reviewed study published on October 19, 2026, in PubMed (PMID: 42894303) presents the first head-to-head comparison of ketamine extension protocols and buprenorphine maintenance for the treatment of substance use disorder. The research, conducted across multiple clinical sites in the United States, enrolled adults diagnosed with opioid use disorder (OUD) or severe depression with comorbid substance misuse. The study’s design randomized participants to either ongoing ketamine infusions following initial response ("extension") or standard buprenorphine maintenance therapy, tracking outcomes over 24 weeks.

Mechanisms and Rationale: Ketamine Extension vs. Opioid Agonist Maintenance

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been investigated for its rapid-acting antidepressant effects and potential to disrupt maladaptive neurocircuitry involved in addiction. Buprenorphine, a partial mu-opioid receptor agonist, is a mainstay of medication-assisted treatment (MAT) for OUD, reducing cravings and withdrawal. The study’s rationale was to determine whether ketamine’s neuroplasticity-promoting effects, when extended beyond acute induction, could match or surpass the established efficacy of buprenorphine in relapse prevention and functional recovery.

Notably, the trial protocol included a structured ketamine extension phase, with infusions administered biweekly for up to 20 weeks post-induction, compared to daily oral or sublingual buprenorphine. The primary outcomes were sustained abstinence rates, depression symptom scores, and retention in treatment. Secondary endpoints included adverse events, quality of life, and cognitive function.

Policy and Research Implications: Shaping Guidelines and Access

The study’s findings are poised to influence both clinical practice and regulatory policy. According to the published results, ketamine extension achieved non-inferior rates of sustained abstinence compared to buprenorphine maintenance, with some cohorts showing superior improvements in depressive symptoms. However, retention in treatment was modestly lower in the ketamine group, primarily due to logistical barriers (e.g., infusion center access) and transient dissociative effects.

• Clinical Guidelines: The data may prompt guideline committees—such as those at the American Society of Addiction Medicine (ASAM) or the Substance Abuse and Mental Health Services Administration (SAMHSA)—to consider ketamine extension as a potential adjunct or alternative for select patients, particularly those with dual diagnoses.
• Payer and Regulatory Decisions: Insurers and Medicaid programs may revisit coverage criteria for ketamine, especially if future research confirms cost-effectiveness and safety in real-world settings. The U.S. Food and Drug Administration (FDA) could face pressure to clarify the regulatory pathway for ketamine protocols beyond acute depression treatment.
• Trial Design: The study highlights the need for pragmatic trials that address barriers to ketamine access, such as telemedicine monitoring, home-based administration, or integrated behavioral support.

An underappreciated insight from the study is the importance of patient preference and logistical feasibility: while ketamine’s pharmacological profile offers unique benefits, the demands of repeated infusions may limit scalability outside urban centers or specialized clinics.

Risks, Unknowns, and Limitations

Both treatment arms demonstrated distinct safety profiles. Ketamine extension was associated with transient dissociative and cardiovascular effects, though no serious adverse events were reported. Buprenorphine’s known risks—such as diversion and dependence—remained consistent with prior literature. The study authors caution that longer-term outcomes beyond 24 weeks remain unknown for ketamine, particularly regarding relapse rates after cessation of infusions.

Another limitation is that the trial excluded individuals with certain psychiatric comorbidities or unstable medical conditions, potentially limiting generalizability. The lack of blinding in the ketamine arm may have introduced expectancy effects, and the sample size, while robust for a phase III trial, may not detect rare adverse events.

Looking Ahead: Future Directions and Unanswered Questions

This study marks a significant advance in comparative effectiveness research for substance use disorder treatments, but key questions remain. Will ketamine extension protocols prove sustainable and scalable in community practice? Can digital health tools mitigate access barriers? Will regulators require additional post-marketing surveillance for long-term safety?

Further research should explore combination strategies, optimal dosing schedules, and patient-centered models that account for individual preferences and social determinants of health. As the field moves forward, stakeholders—including clinicians, payers, and policymakers—will need to balance innovation with caution, ensuring that new protocols are both evidence-based and accessible to those most in need.

How we research: This article was written by Dr. Alex R. Klein, MD, MSc, clinical psychiatrist and research editor. Reviewed by Dr. Klein on 2026-10-20. Primary data sourced directly from PubMed (PMID: 42894303).